Sokal Index for Chronic Myelogenous Leukaemia
Predicts survival in CML (Philadelphia chromosome-positive). Used to stratify risk before starting TKI therapy.
Score interpretation
Sokal Index < 0.8: Low risk. Excellent response to TKI therapy anticipated.
→ Start TKI therapy (imatinib/dasatinib/nilotinib). Aim for CCyR/MMR milestones.
Sokal Index 0.8–1.2: Intermediate risk. Good response expected with TKI.
→ Start TKI therapy. Consider 2nd-generation TKI (dasatinib/nilotinib) for faster deep response.
Sokal Index > 1.2: High risk. Poorer response to imatinib.
→ Prefer 2nd-generation TKI (dasatinib or nilotinib) upfront. Monitor response closely. Consider clinical trial.
Interpretation bands for the Sokal Index. Apply clinical judgement and local guidance.
References
- Sokal JE et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
Related
Curated clinical cross-links plus same-class fallbacks.
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Imatinib · Tyrosine kinase inhibitor (BCR-ABL)
- Methyldopa (Chronic Hypertension in Pregnancy) · Centrally Acting Antihypertensive
- Becaplermin (Recombinant PDGF — Chronic Wounds) · Recombinant Human Platelet-Derived Growth Factor (rhPDGF-BB)
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.